Your browser doesn't support javascript.
Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19.
Selb, Julij; Biteznik, Barbara; Bidovec Stojkovic, Urska; Rituper, Bostjan; Osolnik, Katarina; Kopac, Peter; Svetina, Petra; Cerk Porenta, Kristina; Sifrer, Franc; Lorber, Petra; Trinkaus Leiler, Darinka; Hafner, Tomaz; Jeric, Tina; Marcun, Robert; Lalek, Nika; Frelih, Nina; Bizjak, Mojca; Lombar, Rok; Nikolic, Vesna; Adamic, Katja; Mohorcic, Katja; Grm Zupan, Sanja; Sarc, Irena; Debeljak, Jerneja; Koren, Ana; Luzar, Ajda Demsar; Rijavec, Matija; Kern, Izidor; Flezar, Matjaz; Rozman, Ales; Korosec, Peter.
  • Selb J; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Biteznik B; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Bidovec Stojkovic U; These authors contributed equally.
  • Rituper B; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Osolnik K; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Kopac P; These authors contributed equally.
  • Svetina P; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Cerk Porenta K; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Sifrer F; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Lorber P; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Trinkaus Leiler D; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Hafner T; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Jeric T; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Marcun R; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Lalek N; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Frelih N; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Bizjak M; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Lombar R; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Nikolic V; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Adamic K; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Mohorcic K; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Grm Zupan S; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Sarc I; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Debeljak J; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Koren A; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Luzar AD; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Rijavec M; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Kern I; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Flezar M; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Rozman A; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Korosec P; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
ERJ Open Res ; 8(4)2022 Oct.
Article in English | MEDLINE | ID: covidwho-2153500
ABSTRACT

Background:

The relationship between anti-SARS-CoV-2 humoral immune response, pathogenic inflammation, lymphocytes and fatal COVID-19 is poorly understood.

Methods:

A longitudinal prospective cohort of hospitalised patients with COVID-19 (n=254) was followed up to 35 days after admission (median, 8 days). We measured early anti-SARS-CoV-2 S1 antibody IgG levels and dynamic (698 samples) of quantitative circulating T-, B- and natural killer lymphocyte subsets and serum interleukin-6 (IL-6) response. We used machine learning to identify patterns of the immune response and related these patterns to the primary outcome of 28-day mortality in analyses adjusted for clinical severity factors.

Results:

Overall, 45 (18%) patients died within 28 days after hospitalisation. We identified six clusters representing discrete anti-SARS-CoV-2 immunophenotypes. Clusters differed considerably in COVID-19 survival. Two clusters, the anti-S1-IgGlowestTlowestBlowestNKmodIL-6mod, and the anti-S1-IgGhighTlowBmodNKmodIL-6highest had a high risk of fatal COVID-19 (HR 3.36-21.69; 95% CI 1.51-163.61 and HR 8.39-10.79; 95% CI 1.20-82.67; p≤0.03, respectively). The anti-S1-IgGhighestTlowestBmodNKmodIL-6mod and anti-S1-IgGlowThighestBhighestNKhighestIL-6low cluster were associated with moderate risk of mortality. In contrast, two clusters the anti-S1-IgGhighThighBmodNKmodIL-6low and anti-S1-IgGhighestThighestBhighNKhighIL-6lowest clusters were characterised by a very low risk of mortality.

Conclusions:

By employing unsupervised machine learning we identified multiple anti-SARS-CoV-2 immune response clusters and observed major differences in COVID-19 mortality between these clusters. Two discrete immune pathways may lead to fatal COVID-19. One is driven by impaired or delayed antiviral humoral immunity, independently of hyper-inflammation, and the other may arise through excessive IL-6-mediated host inflammation response, independently of the protective humoral response. Those observations could be explored further for application in clinical practice.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00216-2022

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00216-2022